About: Structural variability, expression profile and pharmacogenetics properties of TMPRSS2 gene as a potential target for COVID-19 therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Structural variability, expression profile and pharmacogenetics properties of TMPRSS2 gene as a potential target for COVID-19 therapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Structural variability, expression profile and pharmacogenetics properties of TMPRSS2 gene as a potential target for COVID-19 therapy
Creator	Dzhaubermezov, Murat Ekomasova, Natalia Kharkov, Vladimir Khitrinskaya, Irina Khusnutdinova, Elza Kolesnikov, Nikita Litvinov, Sergey Maksimova, Nadezhda Markov, Anton Marusin, Andrey Radjabov, Magomed Shtygasheva, Olga Stepanov, Vadim Sukhomyasova, Aitalina Swarovskaya, Maria Zarubin, Aleksei
source	BioRxiv
abstract	The human serine protease TMPRSS2 gene is involved in the priming of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins being one of the possible targets for COVID-19 therapy. TMPRSS2 gene is possibly co-expressed with SARS-CoV-2 cell receptor genes ACE2 and BSG, but only TMPRSS2 demonstrates tissue-specific expression in alveolar cells according to single cell RNA sequencing data. Our analysis of the structural variability of the TMPRSS2 gene based on genome-wide data of 76 human populations demonstrates that functionally significant missense mutation in exon 6/7 in TMPRSS2 gene, was found in many human populations in relatively high frequency, featuring region-specific distribution patterns. The frequency of the missense mutation encoded by the rs12329760, which previously was found to be associated with prostate cancer, is ranged between 10% and 63% being significantly higher in populations of Asian origin compared to European populations. In addition to SNPs, two copy numbers variants (CNV) were detected in the TMPRSS2 gene. Number of microRNAs have been predicted to regulate TMPRSS2 and BSG expression levels, but none of them is enriched in lung or respiratory tract cells. Several well studied drugs can downregulate the expression of TMPRSS2 in human cells, including Acetaminophen (Paracetamol) and Curcumin. Thus TMPRSS2 interaction with the SARS-CoV-2, its structural variability, gene-gene interactions, and expression regulation profiles, and pharmacogenomics properties characterize this gene as a potential target for COVID-19 therapy.
has issue date	2020-06-20(xsd:dateTime)
bibo:doi	10.1101/2020.06.20.156224
has license	biorxiv
sha1sum (hex)	b3aa0023095f334401f257f4417a03c2295fe758
schema:url	https://doi.org/10.1101/2020.06.20.156224
resource representing a document's title	Structural variability, expression profile and pharmacogenetics properties of TMPRSS2 gene as a potential target for COVID-19 therapy
schema:publication	bioRxiv
resource representing a document's body	covid:b3aa0023095f334401f257f4417a03c2295fe758#body_text
is schema:about of	named entity 'variability' named entity 'distribution' named entity 'expression' named entity 'Acetaminophen' named entity 'gene' named entity 'alveolar' named entity 'functionally' named entity 'TMPRSS2' named entity 'SARS-COV-2' named entity 'potential' named entity 'microRNAs' named entity 'variants' named entity 'populations' named entity 'profiles' named entity 'prostate cancer' named entity 'SNPs' named entity 'cells' named entity 'human populations' named entity 'pharmacogenomics' named entity 'Our' named entity 'interactions' named entity 'Number' named entity 'exon' named entity 'gene' named entity 'missense mutation' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'downregulate' named entity 'Paracetamol' named entity 'human populations' named entity 'copy numbers' named entity 'single cell RNA sequencing' named entity 'distribution patterns' named entity 'human populations' named entity 'prostate cancer' named entity 'TMPRSS2' named entity 'pharmacogenetics' named entity 'expression profile' named entity 'viruses' named entity 'severe acute respiratory syndrome' named entity 'protein' named entity 'receptor' named entity 'SARS-CoV-2' named entity 'micro RNA' named entity 'Phenotyping' named entity 'viruses' named entity 'TMPRSS2' named entity 'BSG' named entity 'Acetaminophen' named entity 'prostate' named entity 'missense mutations' named entity 'SARS-CoV-2' named entity 'endothelium' named entity 'peptide' named entity 'up-regulating' named entity 'CNV' named entity 'TMPRSS2' named entity 'cell types' named entity 'SARS-CoV' named entity 'Alternatively spliced transcript variants' named entity 'missense mutations' named entity 'ACE2' named entity 'lung' named entity 'Bioinformatics' named entity 'SNVs' named entity 'proteases' named entity 'NSAIDs' named entity 'sequencing data' named entity 'single cell sequencing'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software